Crispr / cas9-based multiplex gene editing method
By replacing the hU6 promoter as hCtRNA in the CRISPR/Cas9 system, the multi-gene editing plasmid M-PX459 was constructed, which solved the problems of the low efficiency and high cost of the CRISPR/Cas9 system in multi-gene editing, and achieved efficient multi-gene editing. It has promoted the research on multigene control traits and the development of biological breeding.
Patent Information
- Application Number
- PCT/CN2024/074584
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-27
- Filing Date
- 2024-01-30
- Publication Date
- 2024-12-05
AI Technical Summary
The CRISPR/Cas9 system has problems with low efficiency, high cost and long research cycles in multigene editing, especially the lack of effective multigene editing tools in avian cells, which limits the study of genetic mechanisms of multigene control traits.
By replacing the hU6 promoter with hCtRNA, the multi-gene editing plasmid M-PX459 is constructed, and sgRNA tandem assembly of multiple target sites is realized. hCtRNA drives transcription, multiple gene editing is achieved, and target sequence number and editing efficiency are enhanced.
It significantly improves the efficiency of multigene editing, shortens the research cycle, reduces labor costs, and verifies the reliability and applicability of multigene editing in avian cells, promoting the analysis of disease genetic mechanisms and the development of biological breeding.
Smart Images

Figure CN2024074584_05122024_PF_FP_ABST
Abstract
Description
A multiplex gene editing method based on CRISPR / Cas9 Technical Field
[0001] The present application belongs to the field of gene editing technology. Specifically, the present application provides a multiple gene editing method based on CRISPR / Cas9. Background Art
[0002] Gene editing is an emerging genetic engineering technology that modifies specific genes within an organism's genome. Efficient gene editing is a fundamental method for understanding and exploring important biological questions. It is also a crucial tool for precision breeding, gene therapy, and other fields, and holds strategic significance for the development of agriculture and medicine. Gene editing differs from genetic modification (GM) technology. GM primarily focuses on the artificial introduction of foreign genes to achieve specific functions by expressing proteins not already present in an organism. Gene editing, on the other hand, emphasizes the use of technical means to modify existing genes, thereby altering their expression or function to achieve targeted phenotypic changes.
[0003] Currently, the most commonly used gene editing tool is the CRISPR system (Clustered regularly interspaced short palindromic repeats-associated proteins system). CRISPR systems are a defense mechanism developed by bacteria over a long period of evolution to resist invading genetic sequences. They are divided into different types based on the different effector proteins they contain. The CRISPR / Cas9 system is one of the most studied and best characterized systems. CRISPR / Cas9 technology can achieve gene targeting without relying on the synthesis of DNA sequence-specific binding protein modules. Its advantages include a wide range of applications, higher gene editing efficiency, ease of use, and low cost, making it a powerful tool for gene editing. CRISPR / Cas9 technology has been widely used in genetic engineering due to its high efficiency, specificity, and programmability in site-directed mutagenesis of biological genes.
[0004] The working principle of the CRISPR / Cas9 system can be simply summarized as follows: Guided by the guide RNA (gRNA), the Cas9 protein reaches the target site and, by recognizing the PAM sequence of the target DNA, cuts it 3-4 bases upstream of the PAM sequence, creating a site-specific double-strand break (DSB), which then triggers the body to repair the DSB using non-homologous end joining (NHEJ). The repair results typically result in a small number of insertions or deletions (Indels), which trigger the generation of stop codons and prematurely terminate translation of the target gene, thereby achieving gene knockout.
[0005] In recent years, with the rapid development of biotechnology, particularly the launch and implementation of the Human Genome Project (HGP), research on genetic variation has become a hot topic. Leveraging modern analytical biology theories and techniques, we are dissecting the complex traits that control human disease, providing a theoretical foundation for the prevention, diagnosis, and treatment of human diseases and laying a solid foundation for the development of new drugs. In the field of biological breeding, a growing number of studies have revealed that many traits in plants and animals are interconnected. Consequently, modern breeding goals have shifted from prior focus on a few key economic traits, such as high yield, to achieving high yield, high quality, and disease resistance. These complex traits are regulated by multiple key genes. To better improve and utilize these traits, it is necessary to dissect their genetic basis. Genome-wide association analysis methods can help identify potential candidate genes, but molecular biological experiments are still needed to verify the regulatory role of specific gene functions on phenotypes to provide effective insights for disease analysis and biological breeding.
[0006] Currently, the CRISPR / Cas9 system is widely used due to its stability, but the hU6 promoter of the system can only edit a single gene site at a time. This poses a significant experimental limitation for studying traits regulated by multiple genes. Multiple editing, identification, and passage processes need to be repeated to obtain multiple gene knockout cell lines for subsequent gene function verification. If multiple knockout plasmids driven by the hU6 promoter are designed and constructed, multiple gene editing must be performed through co-transfection of multiple plasmids, which greatly reduces the editing efficiency. Both of the above methods will greatly increase the time and labor costs of multi-gene function research. Therefore, the development of co-plasmid tools with multiple gene editing capabilities based on the CRISPR / Cas9 system can improve editing efficiency, shorten research cycles, and reduce labor costs, which is of great significance for studying the genetic mechanisms of traits controlled by multiple genes.
[0007] Summary of the Invention
[0008] Since the length of hCtRNA (75bp) is smaller than the hU6 promoter (241bp) in the CRISPR / Cas9 editing system plasmid PX459, while shortening the length of the original plasmid vector, it maintains the same transcription initiation function as the hU6 promoter. Therefore, the applicant considers that by replacing the original hU6 promoter with hCtRNA, multiple hCtRNAs and gRNAs can be assembled in series into the same PX459 plasmid. M-PX459 can increase the number of target sequences within a limited plasmid length range to achieve the purpose of multiple gene editing. Compared with the PX459 plasmid for single gene knockout, it not only has the ability to edit multiple genes, but also has the same editing efficiency.
[0009] Current studies have shown that under the action of the U6 promoter, by connecting tRNA and gRNA in series, the tandem gRNA can be driven to transcribe and multiple target sites can be edited, but this process still requires the participation of the U6 promoter.
[0010] The applicant was able to initiate gRNA transcription and achieve editing effects solely through hCtRNA, even without a U6 promoter in the plasmid. Furthermore, due to the diversity of tRNA types, different species also have different tRNA sequences suitable for editing multiple genes using tRNA. Currently, no studies have demonstrated the applicability and reliability of hCtRNA for multiple gene editing in avian cells.
[0011] On the one hand, the present application provides a multiple gene editing method based on CRISPR / Cas9, in which a multiple gene editing plasmid M-PX459 is used. The multiple gene editing plasmid M-PX459 is formed by replacing the hU6 promoter in the plasmid PX459 with multiple hCtRNAs; the nucleotide sequence of the hCtRNA is SEQ ID NO.1.
[0012] Furthermore, in the method, sgRNAs for multiple target sites are respectively placed downstream of the multiple hCtRNAs to form multiple hCtRNA-sgRNA combinations.
[0013] Furthermore, in each hCtRNA-sgRNA combination, hCtRNA is used as a promoter to express sgRNA.
[0014] Furthermore, the multiple hCtRNA-sgRNA combinations are arranged in series in the multiple gene editing plasmid M-PX459.
[0015] Furthermore, there are spacer sequences and gRNA scaffold parts between the multiple hCtRNA-sgRNA combinations.
[0016] On the other hand, the present application provides a multiple gene editing plasmid M-PX459, which is formed by replacing the hU6 promoter in the plasmid PX459 with multiple hCtRNAs; the nucleotide sequence of the hCtRNA is SEQ ID NO.1.
[0017] Furthermore, the multiple gene editing plasmid M-PX459 has sgRNAs with multiple target sites placed downstream of the multiple hCtRNAs to form multiple hCtRNA-sgRNA combinations.
[0018] Furthermore, the multiple hCtRNA-sgRNA combinations are arranged in series in the multiple gene editing plasmid M-PX459.
[0019] Furthermore, there are spacer sequences and gRNA scaffold parts between the multiple hCtRNA-sgRNA combinations.
[0020] On the other hand, the present application provides the use of the above-mentioned multiple gene editing plasmid M-PX459 in the preparation of a CRISPR / Cas9 gene editing kit.
[0021] The PX459 plasmid includes the currently commercially available PX459 and various variant versions modified on a phase-by-phase basis.
[0022] The term "plurality" as used herein means more than 2, for example, 2, 3, or 4. The examples show a triple editing method and plasmids, and more multiple editing can be performed depending on the target sequence, reagents, and equipment.
[0023] Currently, no research has been conducted on the use of hCtRNA in gene knockout. We have verified the feasibility of this method through experiments, which can provide technical support for the subsequent analysis of genetic traits controlled by multiple genes and biological breeding, and is of great significance for improving and promoting the development of related industries.
[0024] The invention confirmed the multiple gene editing effect of plasmid M-PX459 and further tested its editing efficiency in multiple gene editing, which can greatly improve the editing efficiency of multiple genes. The experimental plan can accelerate the research process of the genetic mechanism of multi-gene control of phenotypes, and bring great impetus and objective economic benefits to the development of medical and agricultural breeding industries.
[0025] This invention obtains the multiple CRISPR / Cas9 gene editing plasmid M-PX459 for the first time, which can be used for screening and verification of target sequences, as well as the subsequent acquisition of multi-gene knockout cell lines, facilitating the analysis of the regulatory effects of multiple genes on phenotypes, and serving as an important reference for analyzing the genetic mechanisms of diseases and improving the selection of new strains. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 is a schematic diagram of the multiple gene editing plasmid M-PX459;
[0027] Figure 2 is a schematic diagram of the multiple gene editing plasmid M-PX459 after insertion of three target sequences, including three genes: ELOVL1, ELOVL3, and ELOVL4;
[0028] Figure 3A is the Sanger peak plot of ELOVL1;
[0029] FIG3B is the Sanger peak diagram result of ELOVL3;
[0030] Figure 3C is the Sanger peak plot of ELOVL4;
[0031] Figure 4 shows the editing efficiency of the multiplex gene-editing plasmid M-PX459 (identification of E. coli single clones). The percentage of edited types is indicated in parentheses. The target sequence is in light font, the PAM sequence is in bold, italic, and underlined text, and the number to the right indicates the mutation type. "-" indicates a base deletion, "+" indicates a base insertion, and "m" indicates a base substitution. Multiple base mutation types are connected using "&". DETAILED DESCRIPTION
[0032] The following examples are provided to facilitate a better understanding of the present invention, but are not intended to be limiting. These examples are for illustrative purposes only and in no way limit the scope of protection of the present invention.
[0033] Example 1 Construction of multiple gene editing plasmid M-PX459
[0034] Based on the PX459 plasmid, the hU6 promoter (241 bp) was replaced with hCtRNA (75 bp).
[0035] Synthesize hCtRNA and BbsI restriction site sequence: 5'-AGAGGGGGTATAGCTCAGTGGTAGAGCATTTGACTGCAGA TCAAGAGGTCCCCGGTTCAAATCCGGGTGCCCCCT-3' (forward, SEQ ID NO. 1).
[0036] The sequence was synthesized by Beijing Xianghong Biotechnology Co., Ltd. and amplified using primers F1 and R1:
[0037] F1: GCTGGCCTTTTGCTCACATGTAGAGGGGGTATAGCTCAGTG (SEQ ID NO. 2);
[0038] R1: CTTATTTTAACTTGCTATTTCTAGCTCTAAAACAGGTCTTCTCG (SEQ ID NO. 3).
[0039] The PX459 plasmid was digested with Af1III (NEB) and BbsI (NEB), and the 8903-bp PX459 vector backbone was recovered from the gel. The synthesized fragment was cloned into the PX459 vector backbone by homologous recombination (Full Gold CU101) according to the manufacturer's instructions.
[0040] Example 2 Constructing a triple gene editing plasmid targeting ELOVL1, ELOVL3 and ELOVL4 and verifying its editing efficiency.
[0041] Synthesize scaffold+inter+hCtRNA sequence:
[0042] 5'-GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTTAAGCTTGGGCCGCTCGAGGTCTGGATCCGGTACCAAGGTCAGAGGGGGTATAGCTCAGTGGTAGAGCATTTGACTGCAGATCAAGAGGTCCCCGGTTCAAATCCGGGTGCCCCCT-3' (forward, SEQ ID NO. 4).
[0043] The sequence was synthesized by Beijing Xianghong Biotechnology Co., Ltd. The scaffold is an existing sequence in PX459, which guides the connection between the target sequence and the cas9 protein; inter is a spacer sequence, which allows different target sequences to be transcribed separately to avoid mutual influence; hCtRNA is a promoter, which initiates the transcription of the target sequence and scaffold.
[0044] Amplification was performed using this as a template. Different target sequences and restriction sites were added upstream of the amplification primers during primer design to facilitate golden gate connection of multiple target sequences.
[0045] Refer to NCBI duck ELOVL1 (Gene ID: 113844264), ELOVL3 (Gene ID: 101800182) and ELOVL4 (Gene Based on the gene sequence information of ELOVL1 (ELOVL3, ELOVL3), and ELOVL4 (ELOVL4 ID: 101790547), sgRNAs were designed for the first exons of ELOVL1, ELOVL3, and ELOVL4, respectively, and named ELOVL1-sg, ELOVL3-sg, and ELOVL4-sg. ELOVL1-sg was added upstream of F1, ELOVL3-sg was added upstream of F2, and ELOVL4-sg was added downstream of R2. Different linker ends were designed in the primers, and then amplification (as shown in Tables 1 and 2) and gel excision were performed. Two amplification products were obtained using primers F1 / R1 and F2 / R2 (Table 3). The amplification product of F1 / R1 contained the target sequence of ELOVL1, and the amplification product of F2 / R2 contained the target sequences of ELOVL3 and ELOVL4.
[0046] Table 1 Amplification system of insert fragments containing target sequences
[0047] Table 2 Amplification procedures for insert fragments containing target sequences
[0048] Table 3: Primers for amplification of insert fragments containing target sequences
[0049] Table 4: Target sequences of the multiplex gene editing plasmid M-PX459
[0050] The M-PX459 vector was digested and recovered using BbsⅠ restriction endonuclease (Table 4). The specific reaction procedure is as follows (Table 5):
[0051] Table 5: M-PX459 vector enzyme digestion system
[0052] Table 6: M-PX459 vector enzyme digestion procedure
[0053] The linearized vector recovered after enzyme digestion was golden gate ligated with the PCR product (as shown in Tables 6 and 7 below), further transformed and plated, and after sequencing confirmation, a multi-gene knockout vector with accurate ligation was obtained.
[0054] Table 7: Golden Gate connection system
[0055] Table 8: Golden Gate connection procedure
[0056] The cloned bacterial suspension was sent to Beijing Ruibo Xingke Biotechnology Co., Ltd. for sequencing. The sequencing results are shown in the figure, confirming that the plasmid was successfully constructed. The corresponding expression plasmid was extracted for later use.
[0057] Duck immortalized cells CCL-141 were cultured at 37°C, 5% CO2 concentration, and 95% air humidity in EMEM (ATCC, 30-2003) containing 10% fetal bovine serum and 1% double-antibody. When the cells were in good condition, the cells were counted and plated in 12-well plates at a density that allowed them to grow to 80% within 24 hours.
[0058] After 12 hours of plating, transfection was performed when the cell adhesion coverage reached about 70%. Three groups of wild-type expression vector, blank expression vector, and knockout expression vector were set up. Expression vector (1.5 μg) liposomes (4.5 μL) and Opti-MEM (100 μl) were added to each well, mixed and incubated for 15 minutes, and transfected into CCL-141 cells. After 24 hours, the drug screening medium was replaced. After 1 day of drug screening, when the cells grew to 80% to 90%, the cells were taken to extract DNA for knockout efficiency identification. Extraction was performed according to the kit instructions, and the knockout efficiency was analyzed by PCR sequencing. The knockout effect was confirmed by combining the E. coli monoclonal method. The measurement results are shown in Figure 4 and Table 8.
[0059] Table 8 Editing efficiency of multiple gene editing plasmid M-PX459 (peak detection method)
[0060] The above experimental results show that M-PX459 can insert multiple target sequences and guide multiple target sequences for multi-gene knockout, indicating the multi-gene editing ability of M-PX459, which provides an important basis for detecting target sequence effects and improving gene editing efficiency.
Claims
1. A multiple gene editing method based on CRISPR / Cas9, wherein a multiple gene editing plasmid M-PX459 is used, wherein the multiple gene editing plasmid M-PX459 is formed by replacing the hU6 promoter in the plasmid PX459 with multiple hCtRNAs; the nucleotide sequence of the hCtRNA is SEQ ID NO.
1.
2. The method according to claim 1, wherein sgRNAs for multiple target sites are respectively placed downstream of the multiple hCtRNAs to form multiple hCtRNA-sgRNA combinations.
3. The method according to claim 2, wherein each of the hCtRNA-sgRNA combinations uses hCtRNA as a promoter to express sgRNA.
4. According to the method of claim 2 or 3, the multiple hCtRNA-sgRNA combinations are arranged in series in the multiple gene editing plasmid M-PX459.
5. The method according to claim 4, wherein there are spacer sequences and gRNA scaffold parts between the multiple hCtRNA-sgRNA combinations.
6. A multiple gene editing plasmid M-PX459, wherein the multiple gene editing plasmid M-PX459 is formed by replacing the hU6 promoter in the plasmid PX459 with multiple hCtRNAs; the nucleotide sequence of the hCtRNA is SEQ ID NO.
1.
7. According to the multiple gene editing plasmid M-PX459 of claim 6, the multiple gene editing plasmid M-PX459 has sgRNAs of multiple target sites respectively placed downstream of the multiple hCtRNAs to form multiple hCtRNA-sgRNA combinations.
8. According to the multiple gene editing plasmid M-PX459 of claim 7, the multiple hCtRNA-sgRNA combinations are arranged in series in the multiple gene editing plasmid M-PX459.
9. The multiple gene editing plasmid M-PX459 according to claim 8, wherein there are spacer sequences and gRNA scaffold parts between the multiple hCtRNA-sgRNA combinations.
10. Use of the multiple gene editing plasmid M-PX459 according to any one of claims 6 to 9 in the preparation of a CRISPR / Cas9 gene editing kit
Citation Information
Patent Citations
Multi-target sequence sgRNA expression vector based on endogenous tRNA processing system and application of sgRNA expression vector in plant gene editing
CN107475256A
Basic group editor as well as preparation method and application thereof
CN112538500A
Method for determination of restriction efficiency of endonucleases mediating double-strand breaks in DNA target sequences
EP3650557A1
A modular and pooled approach for multiplexed crispr genome editing
US20230265460A1
Method for achieving multi-base editing
WO2023050158A1
